| Literature DB >> 32617395 |
Karime Lucas Uemura1, Dalton Chaves1, Wanderley M Bernardo1, Ricardo Sato Uemura1, Diogo Turiani Hourneaux de Moura1, Eduardo Guimarães Hourneaux de Moura1.
Abstract
Background and aim Gastric peroral endoscopic pyloromyotomy (G-POEM) is a new therapeutic option for refractory gastroparesis (GP). A systematic review and meta-analysis was conducted to assess the effectiveness of G-POEM in refractory GP. For the quality of evidence, we used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Methods We performed a literature search using MEDLINE, Embase, Cochrane library, LILACS and the Science citation index for studies related to G-POEM from the inception of its technique through January 2019. We selected studies that analyzed the gastroparesis cardinal symptom index (GCSI) and 4-hour solid-phase gastric emptying scintigraphy (GES) before and after the procedure to verify the efficacy of G-POEM, the main outcome measured. An analysis was performed using RevMan 5.3. Results Ten studies comprising 281 patients were included in this systematic review. The pooled mean difference in GCSI following the procedure was 1.76 (95 % CI: [1.43, 2.08], I 2 = 72 %). We also performed GCSI subgroup analysis by follow-up duration that showed a pooled mean difference of 1.84 (95 % CI: [1.57, 2.12], I 2 = 71 %). The pooled mean difference in GES after the procedure was 26.28 (95 % CI: [19.74, 32.83], I 2 = 87 %), corresponding to a significant drop in percentage values of the gastric retention 4-hour scintigraphy. Conclusion This meta-analysis demonstrates that G-POEM is effective and shows promising outcomes in the clinical response and gastric emptying scintigraphy for gastroparesis. Therefore, it should be considered in the management of refractory gastroparesis.Entities:
Year: 2020 PMID: 32617395 PMCID: PMC7297609 DOI: 10.1055/a-1119-6616
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1Search strategy and study selection flowchart.
Characteristics of included studies.
| Study | Study design |
Patients No (
| Age | Gender (F:M) | Definition of gastroparesis | Etiology | Procedure duration (minutes) | Myothomy length (cm) | Hospital stay (days) | Clinical success (%/month) | Follow-up (months) | |||
| Diabetes | Idiopathic | Post-surgical | Others | |||||||||||
| Rodriguez J. et al, 2018 | Prospective January 2016 to October 2017 | 100 | 45 ± 14.6 | 85:15 | Patients with ongoing symptoms after at least 6 mo of medical therapy | 21 | 56 | 19 | 4 | 33.8 ± 21.6 | N/A | 1.3 ± 1.05 | N/A | 3 |
| Landreneau et al, 2018 | Retrospective October 2014 to September 2017 | 30 | 44.1 ± 13.5 | 23:7 | Patients who fail to achieve durable response or are unable to tolerate medical therapies | 5 | 19 | 6 | 0 | 33.9 ± 18.8 | N/A | 1.4± 1.0 | N/A | 3 |
| Malik Z. et al, 2018 | Retrospective October 2015 to October 2016 | 13 | 45.7 ± 10.3 | 7:6 | N/A | 1 | 4 | 8 | 0 | 64.4 ± 17.1 | 3.5 ± 0.8 | 2.5 ± 1.4 | 73 % (3mo) | 3 |
| Gonzalez J.M. et al, 2017 | Retrospective January 2014 to April 2016 | 29 | 52.8 ± 17.7 | 19:10 | Symptoms > 6 months, with failure of all prokinetic, and a mean GCSI > 1.5 | 7 | 15 | 5 | 2 | 47 ± 22 | N/A | N/A | 79 % (3mo) 69 % (6mo) | 10 ± 6.4 |
| Xue H.B. et al, 2017 | Retrospective May 2015 to July 2016 | 11/14 | 44 ± 15 | 8:6 | Patients who have failed medical therapy and other interventional therapies (endoscopic Botox injection, gastric electrical stimulation), and patients who have to rely on jejunum tube feeding or total parenteral nutrition (TPN) | 6 | 6 | 1 | 1 | 42.25 ± 12.96 | 3 | 2.46 ± 0.7 | N/A | 2 |
| Mekaroonkamol P. et al, 2019 | Retrospective | 40 | 47.7 ± 15.5 | 35:5 | Patients who failed to respond or could not tolerate to dietary modification, prokinetic or electrical stimulator | 15 | 18 | 5 | 2 | 56.2 ± 24.1 | N/A | N/A | 80 % (1mo) | 18 |
| Hustak R. et al, 2018 | Prospective Since November 2015 | 7 | N/A | N/A | N/A | 2 | 1 | 4 | 0 | 70 min (63–106) | N/A | N/A | 85 % (3mo and 6mo) | 24 |
| Dacha S. et al, 2017 | Retrospective June 2015 to October 2016 | 22 | 44.9 ± 16.3 | 19:3 | Patients who failed to respond to dietary modification, prokinetic or electrical stimulator | 13 | 7 | 1 | 1 | 44.9 ± 15.8 | 2.88 ± 0.3 | 2.5 ± 1.1 dias | 77.3 % | 6.6 ± 4.5 |
| Hernandez-Mondragon O.V. et al, 2017 | Prospective December 2016 to April 2017 | 9 | 42.4 ± 8.5 | 6:3 | Unresponsive medical treatment patients that have a positive GCSI score combined with > 10 % of retention at 4h-GES | 3 | 2 | 4 | 0 | 61.4 ± 7.8 | N/A | N/A | 77 % (3mo) | 3 |
| Jacques J. et al, 2019 | Prospective April 2016 to June 2017 | 20 | N/A | N/A | Persistent symptoms and reduced quality of life despite 6 months of continuous treatment | 10 | 4 | 1 | 5 | 56 min | N/A | 3.75 | 90 % (3mo) | 3 |
Quality assessment studies for case series.
| Joanna Briggs Institute – JBI | Rodriguez et al, 2018 | Landreneau et al, 2018 | Malik et al, 2018 | Gonzalez et al, 2017 | Xue et al, 2017 | Mekaroonkamol et al, 2019 | Hustak et al, 2018 | Dacha et al, 2017 | Jacques J. et al, 2019 | Hernandez-Mondragon O.V. et al, 2017 |
| Were there clear criteria for inclusion in the case series? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Was the condition measured in a standard, reliable way for all participants included inthe case series? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Were valid methods used for identification of the condition for all participants included in the case series? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Did the case series have consecutive inclusion of participants? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Did the case series have complete inclusion of participants? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Was there clear reporting of the demographics of the participants in the study? | N | N | N | N | N | N | N | N | N | N |
| Was there clear reporting of clinical information of the participants? | Y | Y | Y | U | U | N | N | N | N | N |
| Were the outcomes or follow up results of cases clearly reported? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | Y | Y | Y | Y | Y | Y | N | Y | Y | Y |
| Was statistical analysis appropriate? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Overall appraisal: | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include |
Fig. 2Forest plot to compare GCSI before and after G-POEM.
Fig. 3Forest plot to compare GCSI before and after G-POEM without the outlier.
Fig. 4Funnel plot to show the outlier study in GCSI analysis.
Fig. 5Forest plot to compare GCSI subgroup before and after G-POEM.
Fig. 6Forest plot to compare GES before and after G-POEM.
Quality (certainty) of evidence of the studies selected, as determined by the GRADE criteria.
| Certainty assessment | No. of patients | Effect | Certainty | Importance | ||||||||
| No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | GCSI and GES before G-POEM | After G-POEM | Relative (95 % CI) | Absolute (95 % CI) | ||
| GCSI (follow up: range 3 months to 18 months; Scale from: 0 to 5) | ||||||||||||
| 10 | Observational studies | Not serious | Not serious | Not serious | Not serious | None | 281 | 281 | – | MD 1.62 higher (1.45 higher to 1.8 higher) | ⊕⊕○○ Low | Important |
| GES | ||||||||||||
| 10 | Observational studies | Not serious |
Very serious
| Not serious | Not serious | None | 281 | 281 | – | MD 26.62 higher (19.7 higher to 33.55 higher) | ⊕○○○ Very low | Important |
| GCSI subgroup | ||||||||||||
| 9 | Observational studies | Not serious |
Serious
| Not serious | Not serious | Publication bias strongly suspected | 375 | 375 | – | MD 1.79 higher (1.49 higher to 2.09 higher) | ⊕○○○ Very low | Important |
CI, confidence interval; MD, mean difference; GCSI, gastroparesis cardinal symptom index; GES, gastric emptying scintigraphy; G-POEM, gastric peroral endoscopic pyloromyotomy.
Heterogeneity above 75 %
Heterogeneity between 50 % and 75 %
Excluded studies.
| Study | Study Design |
Patients No (
| Reason for exclusion |
| Jiaxin Xu et al, 2018 | Retrospective Single center – China | 16 | GES 4 h missing data |
| Kahaleh M. Et al, 2018 | Case series Multicenter – USA/France | 33 | Missing SD data |
| Khashab M. et al, 2017 | Retrospective Multicenter – USA/Asia/South America | 30 | GCSI missing data / Invalidated symptoms questionnaire |
| Allemang M.T. et al, 2017 | Retrospective Single center – USA | 57 | GES missing data |
| Shlomovitz E. et al, 2015 | Retrospective Single center – USA | 7 | GCSI missing data / Invalidated symptoms questionnaire |
Fig. 7Forest plot to demonstrate clinical success.
Fig. 8Adverse events.
Adverse events severity.
| Study | Adverse events (procedure-related) | Adverse event (type) | Severity |
| Rodriguez J. et al, 2018 | 10 | 4 bleeding 1 capnoperitoneum and subcutaneous emphysema (diagnostic laparoscopy) 2 severe dehydration 3 repeat upper endoscopy | Moderate Severe Moderate Moderate |
| Landreneau et al, 2018 | 1 | 1 abdominal pain (needed diagnostic laparoscopy) | Severe |
| Malik Z. et al, 2018 | 1 | 1 pulmonary embolism | Severe |
| Gonzalez J.M. et al, 2017 | 9 | 4 pneumoperitoneum 1 pneumoperitoneum and abscess 2 bleeding 1 stricture (delayed) | Mild Severe Moderate Moderate |
| Xue H.B. et al, 2017 | 0 | none | – |
| Mekaroonkamol P. et al, 2019 | 3 | 1 tension capnoperitoneum 1 bleeding ulcer 1 exacerbation of pre existing chronic obstructive pulmonary disease | Mild Moderate Moderate |
| Hustak R. et al, 2018 | 1 | 1 bleeding ulcer | Moderate |
| Dacha S. et al, 2017 | 1 | 1 tension pneumoperitoneum | Mild |
| Hernandez-Mondragon O.V. et al, 2017 | 4 | 4 abdominal pain | Mild |
| Jacques J. et al, 2019 | 28 | (8 not related to G-POEM) 3 gastric perforation 1 abdominal pain (needed reoperation) 8 procedural abdominal pain 1 epistaxis 7 GI bleeding | Mild Severe Mild Mild Moderate |